Vancouver, British Columbia — August 14, 2025 — Leads & Copy — Blackbird Critical Metals Corp. has entered a definitive share purchase agreement to acquire Lir Life Sciences Inc. for at least 21,807,143 common shares of Blackbird, subject to CSE approval and Blackbird shareholder approval.
The acquisition is a “Fundamental Change” under CSE policy. Following the closing, Blackbird intends to continue Lir Life Science’s business under the name “Lir Life Sciences Corp.”
Lir Life Sciences will complete a private placement for minimum gross proceeds of $1,000,000 at $0.35 per subscription receipt before closing. Blackbird will consolidate shares on a 1.5:1 basis before closing.
Certain shares of the Resulting Issuer will be subject to resale restrictions. Directors and officers of Blackbird will resign upon closing, except for Gurdeep Bains. The new directors and officers will include: Dr. Edward Mills, Harry Nijjar, Constantine Carmichel, Kevin May, and Dr. Mark Dybul.
Trading in Blackbird shares is halted pending CSE requirements. Lir Life Sciences is focused on transdermal drug delivery for metabolic disorders, particularly obesity, and has access to a proprietary drug delivery platform through a licensing agreement with Sinedore Pharmaceuticals Inc.
Blackbird is a Canadian mineral exploration company focused on critical metal properties used in green technologies.
Contact: Jatinder Sandhar, CFO, Email: jtsandhar@gmail.com, Telephone: 604-308-9913
Source: Blackbird Critical Metals Corp.
